GLP-1s: Distilling Signal From Noise – Watch on Demand

In the last year, obesity drugs have dominated headlines and taken center stage, representing an emerging market that has potential to transform both individual human health and the healthcare industry. But instead of getting lost in speculation, it’s important to ground conversations in today’s market realities.

We recently partnered with STAT for a thought-provoking webinar conversation about the rapidly transforming obesity market, driven by GLP-1s. Industry experts shared the trends they’re tracking, and the questions biopharma executives should be asking themselves right now about the market for GLP-1s.

Expert speakers included:

• Jesse McQuarters,

  Branded Content Editor at STAT

• Rita Glaze-Rowe,

  President, Transformative Healthcare Markets, Real Chemistry

• Courtney Younglove, M.D.,

  Founder & Medical Director, Heartland Weight Loss and WellMi and Chief Medical Officer, Journeys Metabolic

Learn more about our research and expertise on GLP-1s on our Transformative Healthcare Markets page or contact us at TransformativeHealthcareMarkets@realchemistry.com.

Want more insights on the people, stories and ideas that are changing healthcare into what it should be? Subscribe to our Healthcare Connection newsletter and get transformative ideas delivered to your inbox every month.